Research location
Ostrava
Czechia
Advertisement
Research activity in Ostrava
CzechiaCureCurrent currently publishes aggregate city-level research activity for this location: 304 trials and 366 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ostrava
304 linked trials · page 1 of 7A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation
RECRUITING
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 2 site observations
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation
RECRUITING
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245 · 2026-08-07 · 1 site observation
RECRUITING
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)NCT07625644 · 2026-08-04 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553 · 2026-07-08 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 1 site observation
RECRUITING
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 · 2026-03-03 · 1 site observation
RECRUITING
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 · 2026-02-09 · 1 site observation
RECRUITING
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)NCT07222332 · 2026-02-05 · 1 site observation
RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 in Patients With DepressionNCT07300969 · 2025-12-16 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 · 2025-12-15 · 1 site observation
RECRUITING
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · 2025-09-30 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 6 site observations
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 3 site observations
RECRUITING
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · 2025-06-26 · 1 site observation
RECRUITING
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · 2025-06-26 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 3 site observations
RECRUITING
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257 · 2025-06-19 · 1 site observation
RECRUITING
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation
RECRUITING
Early Detection of CTEPH in Patients After APENCT06865326 · 2025-03-07 · 1 site observation
RECRUITING
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation
RECRUITING
24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential TremorNCT06570421 · 2024-07-19 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 2 site observations
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation
RECRUITING
Gastric Pathophysiology in DiabetesNCT06068114 · 2022-10-05 · 2 site observations
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Small Bowel DiversionNCT06374368 · 2019-05-01 · 2 site observations
RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · 2026-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · 2025-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
CRF2 Agonist for the Treatment of Worsening Heart FailureNCT06815471 · 2025-08-07 · 1 site observation
SUSPENDED
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 · 2025-07-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · 2025-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THSNCT07108166 · 2025-04-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · 2025-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisNCT06754462 · 2025-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)NCT06558799 · 2024-10-14 · 1 site observation
TERMINATED
Snapshot Study on Patients With Heart FailureNCT06469814 · 2024-09-27 · 1 site observation
ENROLLING_BY_INVITATION
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 2 site observations
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.